This is a routine filing for an upcoming annual meeting. The key development is the addition of two new directors, which may be of interest to governance-focused investors. No immediate trading action is suggested based on this filing alone.
GERN drugs
GERN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 8 $1.71entry
- T+1 · 7mo ago +2.92%α +2.35% · $1.76
- T+5 · 7mo ago −1.17%α −4.69% · $1.69
- T+20 · 7mo ago −3.51%α −12.05% · $1.65
- T+60 · 4mo ago −20.47%α −30.92% · $1.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Geron Corporation has filed its definitive proxy statement (DEFA14A) ahead of its 2026 Annual Meeting, following the recent appointment of two new directors, Patricia S. Andrews and Constantine Chinoporos, as disclosed in an 8-K filing. The proxy materials detail the board's nominees, compensation, and governance practices, with no indication of an activist campaign or contested vote.
Key Financial Metrics
Key Facts
- Filed a DEFA14A proxy statement for the 2026 Annual Meeting of Stockholders.
- Recent 8-K filing (March 26, 2026) announced the appointment of two new directors, Patricia S. Andrews and Constantine Chinoporos, to the Board.
- The proxy statement is for routine director elections and corporate governance matters.
- No activist campaign or contested vote is indicated in the filing.
Financial Impact
No direct financial impact from this routine filing.
Risk Factors
- Routine filing with no immediate financial or strategic implications.
- Potential for future governance changes as new directors integrate.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0000886744-26-000025 |
| Document: 0000886744-26-000025-index-headers.html | 0000886744-26-000025 |
| Document: 0000886744-26-000025-index.html | 0000886744-26-000025 |
| Document: 0000886744-26-000025.txt | 0000886744-26-000025 |
Track record
11 reports on GERN
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $0.9742 Now $0.9400 −3.51% settles Nov 17
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $0.9965 to $0.9419 Now $0.9400 −5.67% ▼ −5.48% −3.79% vs SPY
- Nov 4, 202612d ago 8-K Mixed 6/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $1.08 to $1.02 Now $0.9400 −12.96% ▼ −5.56% −4.64% vs SPY
- Oct 28, 202619d ago 8-K Bearish 6/10 Entry $0.9462 to $0.9501 Now $0.9400 +0.66% ▼ −0.41% −5.14% vs SPY
- Oct 19, 202628d ago Press Release Neutral 2/10 Entry $1.24 to $1.16 Now $0.9400 −24.19% ▼ −6.85% −6.88% vs SPY
- Sep 18, 20268w ago Press Release Neutral 2/10 Entry $1.30 to $1.25 Now $0.9400 −27.69% ▼ −3.85% −2.83% vs SPY
- Apr 22, 202629w ago Press Release Neutral 1/10 Entry $1.55 to $1.52 Now $0.9400 −39.35% ▼ −2.26% −2.31% vs SPY
- Apr 7, 202631w ago DEFA14A Neutral 3/10 Viewing Entry $1.71 to $1.69 Now $0.9400 −45.03% ▼ −1.17% −4.69% vs SPY
- Mar 30, 202633w ago Court Ruling Neutral 2/10 Entry $1.41 to $1.74 Now $0.9400 −33.33% ▲ +23.40% +19.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers